696 results about "Regimen" patented technology

The disclosure provides methods for treating a patient in need thereof comprising co-administering to the patient a therapeutically-effective dose of psilocybin and one or more benzodiazepines. The present disclosure also provides methods to reduce the SSRI washout period in patients prior to administration of psilocybin therapy.

Disclosed are RAS(ON) multi-selective inhibitor compositions and methods of treating RAS protein-related diseases or disorders using an intermittent dosing regimen. RAS(ON) multi-selective inhibitors having tight binding to cyclophilin A (CypA) result in high exposure levels, prolonged tissue retention, and / or slow clearance rates, thereby increasing the risk of inhibition of wild-type RAS in normal tissues. Accordingly, provided herein are methods for the safe and effective dosing of low KD1 RAS(ON) multi-selective inhibitors using an intermittent dosing regimen. Also provided are methods of selecting or identifying such RAS(ON) multi-selective inhibitors suitable for intermittent administration.

The present disclosure provides methods and dosing regimens for the treatment of depression (e.g., treatment resistant depression) with a mucoadhesive composition comprising N, N-dimethyltryptamine (DMT) or a pharmaceutically acceptable salt thereof.

A neurostimulation system that has a programmer which has a power supply and processors with processing circuitry and a neurostimulation device which has power supply, processors and communication circuitry for providing communication with a neurostimulation device as well as communication circuitry for communication with the programmer. The neurostimulation system is configured to deliver treatment to a patient in accordance with a clinician prescribed protocol of a regimen. The neurostimulation system compares a delivered therapy treatment which has a treatment protocol to a defined treatment protocol of a prescribed treatment and adjusts the prescribed treatment stimulation parameters to compensate for a difference between the delivered neurostimulation therapy treatment and the prescribed treatment protocol for closely approximating the prescribed treatment protocol.

The disclosure relates to methods, compositions, and combinations for detoxification in a patient comprising performing therapeutic plasma exchange (TPE) on the patient. The disclosure also relates to methods, compositions, and combinations for removing toxins in a patient as a result of chronic exposure to the toxins, comprising performing one or more TPE sessions on the patient and administering an oral composition to the patient. The methods, compositions, and combinations of the disclosure may also be used to replenish biomarkers indicative of a healthy state of the body in order to improve immune system function or patient longevity, and / or reduce oxidative stress or inflammation. The methods, compositions, and combinations of the disclosure may also be used to reduce the level of atherosclerosis, improve cognitive function, prevent early cancer development, promote immune health, and / or treat health conditions or diseases such as autoimmune diseases, cancers, Alzheimer's disease, Parkinson's disease, chronic fatigue syndromes, or fibromyalgia. Additionally, the methods, compositions, and combinations of the disclosure may comprise an intravenous supplementation, wherein each TPE session is followed by administration to the patient of an IV composition. The disclosure further relates to oral compositions and IV compositions for use in the methods, compositions, and combinations of the disclosure.

Provided herein is, among other things, is a method of treating cancer using an improved intermittent dosing regimen for Azenosertib, or a pharmaceutically acceptable salt thereof, administration to achieve a highly efficacious, safe and tolerable dosing regimen to treat many different types of cancers. In one aspect, the method of treating cancer comprises administering a daily dose of Azenosertib, or a pharmaceutically acceptable salt thereof, (e.g., greater than about 350 mg) in accordance with an improved intermittent dosing cycle, wherein the intermittent dosing cycle comprises one or more dosing weeks with each dosing week comprising between about 2-7 consecutive dosing days and between about 1-7 days without dosing. In some embodiments, the intermittent dosing cycle is repeated wherein the dosing weeks are separated by a break of one, two or more weeks. In some aspects, Azenosertib, or a pharmaceutically acceptable salt thereof, is administered as a combination therapy.

The invention relates to the technical field of medical decision and artificial intelligence, and discloses an artificial intelligence-driven new adjuvant therapy scheme optimization method and system for antral sinus cancer, and the method comprises the steps: S1, obtaining clinical data of a antral sinus cancer patient, and carrying out the preprocessing; s2, screening core features by adopting an iterative ReliefF algorithm, and constructing composite features; s3, constructing a prediction model based on a Bayesian optimization K-nearest neighbor algorithm, taking the composite features as input of the prediction model to predict treatment response, and outputting individual tumor recession grade probability distribution of the patient; s4, taking the tumor recession grade probability distribution as a core component of a state space, inputting the tumor recession grade probability distribution into a double-layer reinforcement learning framework based on a penalty mechanism to optimize a treatment decision, and outputting a personalized treatment strategy parameter set; and S5, performing real-time scanning and verification on the drug dosage parameters in the strategy parameter set, and outputting a final approved personalized treatment scheme. The precision and intelligent level of gastric antrum cancer treatment is improved.

The invention discloses a device and method for precise administration of traditional Chinese medicine preparations. The device comprises a control module used for obtaining physical information and disease information of a to-be-administered user, performing multi-dimensional feature extraction to obtain multi-dimensional feature information, and generating a corresponding dynamic prescription and an individual administration scheme according to a first knowledge graph; obtaining a second knowledge graph; the traditional Chinese medicine efficacy association network constructs a synergistic effect relationship of different medicinal materials through a graph neural network; the medicine warehouse management module comprises a multi-temperature-zone medicine storage unit and a medicinal material weighing unit, and the multi-temperature-zone medicine storage unit divides independent storage spaces according to medicinal material attributes; the medicine feeding robot comprises a medicinal material extracting and packaging all-in-one machine; the control module controls the medicine library management module to dispense the medicinal materials according to the dynamic prescription, and controls the medicine delivery robot to perform directional extraction, concentration adjustment and time-phased packaging on the dispensed medicinal materials according to an individual taking scheme; the individualized administration regimen includes a pulsed administration timing calculated based on the metabolic cycle of the patient.

The invention discloses an anesthesia depth accurate prediction system and method based on time sequence alignment. The method comprises the steps that a cross-modal joint time sequence characteristic data matrix is acquired and generated; outputting a time sequence alignment feature sample; outputting a future advanced prediction label set; obtaining a first-stage anesthesia depth prediction model; in the first anesthesia depth prediction model training stage, a logic auditing link is introduced, and a self-adaptive online updating model is formed; starting an anti-fact dose simulation module, and outputting a candidate anti-fact administration scheme set; and inputting the candidate anti-factual administration scheme set into a dynamic security constraint optimizer, rejecting non-compliant schemes by the dynamic security constraint optimizer according to single maximum dose limitation, single additional dose and administration times in a minimum administration interval, and outputting an optimal administration suggestion. According to the method, combined classification judgment is carried out on the anesthesia state grade and the change trend of each prediction step, and the sensitivity of clinical risk identification and abnormal situation early warning is effectively improved.

The invention provides an in vitro method for determining the prognosis of a patient with stroke comprising: (i) determining, in a sample isolated from the patient, the expression level of at least one miRNA selected from the group consisting of miR-376c-3p, miR-199a and combinations thereof, (ii) comparing the level of expression obtained in step (i) with a corresponding reference value, wherein if the expression level determined in step (i) is higher than the corresponding reference value, the patient is considered to have a bad prognosis. The invention also provides an in vitro method for deciding or recommending whether to initiate a medical regimen in a patient with stroke, and an in vitro method for determining the response of a patient already diagnosed with stroke, to a medical regimen for treating stroke. The invention further provides a miRNA inhibitor of a miRNA selected from the list consisting of miR-376c- 3p, miR-199a and combinations thereof, for use in the treatment or prevention of stroke in a patient. The invention also provides a combination of miRNAs comprising said miRNA inhibitor, and a pharmaceutical composition for use in the treatment or prevention of stroke.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

Provided herein are pharmaceutical compositions comprising a compound of having Formula I as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more pharmaceutical excipients, wherein the composition is in a unit dosage form; and methods for treating cancer modulated by HER2 in a subject, the method comprising administering to the subject an effective amount of the pharmaceutical composition or a compound having Formula II as described in this disclosure, or a pharmaceutically acceptable salt thereof, and optionally one or more additional therapeutic agents.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. The methods may comprise gene-editing at least a portion of the TILs to enhance their therapeutic efficacy. Such TILs find use in therapeutic treatment regimens.

The present invention relates to methods for treating or reducing the severity of thyroid eye disease. In particular, the present invention provides methods for treating or reducing the severity of thyroid eye disease in patients in need thereof comprising administering an IGF-1R antagonist antibody according to specific dosage regimens. Pharmaceutical compositions comprising the IGF-1R antagonist antibody for use in the methods are also described.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention is a method for treating levodopa naïve patients with Parkinson's disease by orally administering a controlled release levodopa formulation twice a day to the levodopa naïve patient and the method provides an improvement of a patient's motor state as determined by patient's Parkinson's disease diary, provides a reduction of from about 10%-40% in the patient's tremor, dyskinesia, and / or mobility and / or provides a reduction in the patient's Movement Disorders Society version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) scores by at least 3 points.

The present invention provides improved and / or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs. Such TILs find use in therapeutic treatment regimens.

The invention discloses an excrement character recognition and drug delivery closed-loop control method and system, and the system comprises an excrement collection and preprocessing module which is used for carrying out the automatic collection, preliminary physical and chemical character detection and sample preprocessing of the excrement of a patient; the multi-modal data analysis module is used for carrying out deep fusion analysis on the original multi-modal data output by the excrement collection and preprocessing module and carrying out diarrhea type diagnosis and severity evaluation; the drug delivery closed-loop control module is used for accurately and dynamically infusing drugs according to the diagnosis result of the multi-modal data analysis module; and the man-machine interaction and early warning module is used for monitoring and intervening the state of the system by medical staff and receiving important alarms. According to the invention, objective and continuous evaluation of excrement properties is realized, the drug dosage and scheme can be dynamically adjusted according to the properties, and the accuracy, individualization level and safety of diarrhea treatment of critical patients are significantly improved.

Provided is a method of treating malignant tumor by an azabicyclic compound, particularly, with eye disorder reduced. The present invention provides a method for treating malignant tumor, comprising administering an effective amount of 3-ethyl-4-[3-(1-methylethyl)-4-[4-(1-methyl-1H-pyrazol-4-yl)-1H-imidazol-1-yl]-1H-pyrazolo[3,4-b]pyridin-1-yl]benzamide (compound 1) or a salt thereof to a patient in need thereof according to a dosing regimen, wherein the dosing regimen comprises administering the compound 1 or the salt thereof at a dose from 40 mg / body / day to 240 mg / body / day in terms of the amount of the compound 1 for consecutive days, and then providing a withdrawal period of at least 2 days.

A diabetes management system adapted to determine adherence for a subject in treatment according to a basal insulin regimen, the system being adapted to receive regimen data. BG data and insulin injection data. If one or more insulin injections have not been received in accordance with the prescribed regimen and thus are missing, the system is adapted to calculate for each missing injection an expected dose response BG value. By comparing received BG data, corresponding to the missing insulin injections, it can be determined for a given confidence interval whether or not the subject has been in adherence with the basal insulin regimen.

Methods, systems and apparatus are described for classifying one or more candidate molecule drugs in relation to one or more desired target conditions for use in downstream processing of drug optimization. A candidate molecule drug inference dataset is received for one or more molecule drugs, the candidate molecule drug dataset comprising data representative of a set of physiochemical values for each candidate molecule drug and a set of pharmacokinetic (PK) values associated with a dosage regimen and target in relation to each candidate molecule drug, and where each candidate molecule drug of the candidate molecule drug dataset is classified as a large molecule drug. For each candidate molecule drug of the candidate molecule drug inference dataset, the corresponding set of physiochemical values and set of PK values for the dosage regimen and target are applied to a machine learning (ML) model configured for classifying whether each candidate molecule drug meets one or more desired conditions associated with pharmacological or pharmacodynamic effects. The ML model is trained using an ML algorithm to train model parameters defining the ML model for classifying whether each candidate molecule drug meets the one or more desired conditions based on a training dataset comprising data representative of a plurality of molecule drugs, each molecule drug represented by a corresponding set of physiochemical values and a set of PK values associated with the dosage regimen and the target, and annotated in relation to corresponding pharmacological or pharmacodynamic effects, responses and / or values in relation to the desired conditions. A set of candidate molecule drugs satisfying the desired conditions is output for downstream processing of drug optimization.

The inhalation suspension preparation containing the SGC receptor stimulant comprises the SGC receptor stimulant with an effective therapeutic dose or pharmaceutically acceptable salt of the SGC receptor stimulant, and pharmaceutically acceptable auxiliary materials of the suspension preparation, the pharmaceutically acceptable auxiliary materials of the suspension preparation comprise at least one of a surfactant, a pH regulator, an osmotic pressure regulator and a metal complexing agent; the inhalation suspension preparation containing the riociguat shows good lung absorption efficiency, is beneficial to reaching the same or better treatment level by reducing the administration dosage, can directly act on a diseased region through an administration route, takes effect more quickly compared with oral administration of the riociguat, and has a good application prospect. Gastrointestinal discomfort and systemic hypotension side effects caused by gastrointestinal tract contact and absorption entering a circulatory system can be avoided, the treatment cycle of an oral dosage form dosage titration administration scheme is shortened, and a better treatment scheme is provided for relieving dyspnea and syncope symptoms of pulmonary hypertension patients treated at home.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention provides a pharmaceutical composition for sensitizing EGFR-TKI drug-resistant tumor treatment and application of the pharmaceutical composition. The pharmaceutical composition comprises a) a therapeutically effective amount of decitabine and b) a therapeutically effective amount of an EGFR tyrosine kinase inhibitor. The combined treatment scheme provided by the invention directly aims at the EGFR-TKI drug-resistant tumor problem, has a clear treatment target spot and relatively high clinical transformation potential, provides a new treatment choice for patients, and provides a theoretical basis and a practical reference for formulating a future individualized treatment scheme.

Disclosed are formulations and dosage forms of avermectins, and particularly of ivermectin. The disclosed compositions may be used in methods for the treatment and prevention of pain in humans.

The invention relates to the technical field of medicines, and discloses an adeno-associated virus (AAV) injection carrying an artificial chemical genetics receptor gene sequence, and a combinatorial chemical genetics scheme formed by the adeno-associated virus injection and a small molecule agonist quetiapine. Compared with the traditional chemical genetics, the medicine quetiapine with smaller clinical side effect is used as the activating agent for the first time, and a novel chemical genetics system with lower medication risk is developed. The system can effectively reduce the excitatory activity of neurons, avoids the medication risk caused by clozapine or other non-market traditional chemical genetics activators, and improves the feasibility of clinical transformation of the chemical genetics system. In the aspect of application of a novel or traditional chemical genetics system, the combined treatment scheme is applied to intervene in Parkinson's disease (PD) for the first time, abnormal activities of STN and related loops of PD patients can be inhibited, and the dyskinesia symptom can be remarkably improved.

Provided herein are dosing regimens and methods for treating conditions and diseases characterized by a reduced expression or function of NaV1.1 protein by modulating splicing of a pre-mRNA encoded by an SCN1A gene. The dosing regimens and methods can be used to treat Dravet Syndrome or other conditions and diseases.

The present invention provides specific dosage regimens for the treatment of generalized pustular psoriasis (GPP) with anti-interleukin-36R antibodies (anti-IL36R antibodies) which dosage regimens surprisingly provide for the rapid and sustained remission of pathological symptoms of GPP including e.g., flares caused by GPP.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.

The invention is a method for treating patients with Parkinson's disease by orally administering a controlled release levodopa formulation and the method provides an improvement of a patient's total post-dose “Off” time, total post dose “On” time and total post dose “Good On” time compared to post-dose of treatment regimens with oral immediate release levodopa tablets.